These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 24820924)

  • 1. Effectiveness and tolerability of second-line therapy with vildagliptin versus other oral agents in type 2 diabetes (EDGE): post-hoc subanalysis of the Belgian data.
    Hoste J; Daci E; Mathieu C
    Acta Clin Belg; 2014 Jun; 69(3):171-6. PubMed ID: 24820924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness and tolerability of second-line treatment with vildagliptin versus other oral drugs for type 2 diabetes in a real-world setting in the Middle East: results from the EDGE study.
    Saab C; Al-Saber FA; Haddad J; Jallo MK; Steitieh H; Bader G; Ibrahim M
    Vasc Health Risk Manag; 2015; 11():149-55. PubMed ID: 25750538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of vildagliptin versus other oral antidiabetes drugs as add-on to sulphonylurea monotherapy: Post hoc analysis from the EDGE study.
    Prasanna Kumar KM; Phadke U; Brath H; Gawai A; Paldánius PM; Mathieu C
    Prim Care Diabetes; 2016 Dec; 10(6):452-458. PubMed ID: 27353459
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and tolerability of vildagliptin-based versus comparative dual therapy in type 2 diabetes : Results of the Austrian subpopulation of the EDGE study.
    Brath H; Bialek C; Gingl E; Resl M; Prager R; Ratzinger M
    Wien Klin Wochenschr; 2015 Apr; 127(7-8):250-5. PubMed ID: 25576329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness and tolerability of second-line therapy with vildagliptin vs. other oral agents in type 2 diabetes: a real-life worldwide observational study (EDGE).
    Mathieu C; Barnett AH; Brath H; Conget I; de Castro JJ; Göke R; Márquez Rodriguez E; Nilsson PM; Pagkalos E; Penfornis A; Schaper NC; Wangnoo SK; Kothny W; Bader G
    Int J Clin Pract; 2013 Oct; 67(10):947-56. PubMed ID: 23961850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-life efficacy and safety of vildagliptin compared with sulfonylureas as add-on to metformin in patients with type 2 diabetes mellitus in Germany.
    Göke R; Gruenberger JB; Bader G; Dworak M
    Curr Med Res Opin; 2014 May; 30(5):785-9. PubMed ID: 24328429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Efficacy and safety of vildagliptin as a second-line therapy vs other oral antidiabetic agents in patients with type 2 diabetes: Czech results within the worldwide prospective cohort EDGE study].
    Haluzík M; Veselá V; Gerle J; Brada M; Dohnalová L; Edelsberger T; Houdová J
    Vnitr Lek; 2013 Dec; 59(12):1049-56. PubMed ID: 24350936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differences in glycemic control across world regions: a post-hoc analysis in patients with type 2 diabetes mellitus on dual antidiabetes drug therapy.
    Brath H; Paldánius PM; Bader G; Kolaczynski WM; Nilsson PM
    Nutr Diabetes; 2016 Jul; 6(7):e217. PubMed ID: 27376699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative effectiveness of vildagliptin in combination with other oral anti-diabetes agents in usual-care conditions: the EDGE-Latin America study.
    Mendivil CO; Márquez-Rodríguez E; Angel ID; Paz G; Rodríguez C; Almada J; Szyskowsky O
    Curr Med Res Opin; 2014 Sep; 30(9):1769-76. PubMed ID: 24867177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-life safety and efficacy of vildagliptin as add-on to metformin in patients with type 2 diabetes in Turkey--GALATA study.
    Ayvaz G; Keskin L; Akin F; Dokmetas HS; Tasan E; Ar IB; Uren E;
    Curr Med Res Opin; 2015 Apr; 31(4):623-32. PubMed ID: 25697921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24-week, double-blind, randomized trial.
    Pan C; Yang W; Barona JP; Wang Y; Niggli M; Mohideen P; Wang Y; Foley JE
    Diabet Med; 2008 Apr; 25(4):435-41. PubMed ID: 18341596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the dipeptidyl peptidase-4 inhibitor vildagliptin and the sulphonylurea gliclazide in combination with metformin, in Muslim patients with type 2 diabetes mellitus fasting during Ramadan: results of the VECTOR study.
    Hassanein M; Hanif W; Malik W; Kamal A; Geransar P; Lister N; Andrews C; Barnett A
    Curr Med Res Opin; 2011 Jul; 27(7):1367-74. PubMed ID: 21568833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and safety of vildagliptin and vildagliptin add-on to metformin in real-world settings in Egypt - results from the GUARD study.
    Shelbaya S; Rakha S
    Curr Med Res Opin; 2017 May; 33(5):797-801. PubMed ID: 28303721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effectivity and security of vildagliptin as additional treatment for Type 2 diabetes mellitus in real-life conditions in Mexico. EDGE Study subanalysis].
    Márquez-Rodríguez E; Brea-Andrea E; Rajmet-Hace VA; Salinas-Salinas J; Mariño-Rojas F
    Gac Med Mex; 2016; 152(4):457-64. PubMed ID: 27595248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of metformin plus vildagliptin compared with metformin plus sulphonylurea for the treatment of patients with type 2 diabetes mellitus: a Portuguese healthcare system perspective.
    Viriato D; Calado F; Gruenberger JB; Ong SH; Carvalho D; Silva-Nunes J; Johal S; Viana R
    J Med Econ; 2014 Jul; 17(7):499-507. PubMed ID: 24708176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination therapy with metformin plus vildagliptin in type 2 diabetes mellitus.
    Guarino E; Nigi L; Patti A; Fondelli C; Dotta F
    Expert Opin Pharmacother; 2012 Jun; 13(9):1377-84. PubMed ID: 22397507
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Continuous glucose profiles with vildagliptin versus sitagliptin in add-on to metformin: results from the randomized Optima study.
    Guerci B; Monnier L; Serusclat P; Petit C; Valensi P; Huet D; Raccah D; Colette C; Quéré S; Dejager S
    Diabetes Metab; 2012 Oct; 38(4):359-66. PubMed ID: 22809630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of vildagliptin relative to sulfonylurea as dual therapy with metformin (or as monotherapy) in Muslim patients with type 2 diabetes fasting during Ramadan in the Middle East: the VIRTUE study.
    Hassoun AA; Al-Arouj M; Ibrahim M
    Curr Med Res Opin; 2017 Jan; 33(1):161-167. PubMed ID: 27684469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vildagliptin: clinical trials programme in monotherapy and combination therapy for type 2 diabetes.
    Rosenstock J; Fitchet M
    Int J Clin Pract Suppl; 2008 Mar; (159):15-23. PubMed ID: 18269437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. One-year safety, tolerability and efficacy of vildagliptin in patients with type 2 diabetes and moderate or severe renal impairment.
    Kothny W; Shao Q; Groop PH; Lukashevich V
    Diabetes Obes Metab; 2012 Nov; 14(11):1032-9. PubMed ID: 22690943
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.